Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Gene mutation site for predicting anti-HER2 therapeutic drug reactivity of patients with breast cancer and application thereof

A technology for drug response and breast cancer, applied in the medical field, can solve problems such as restricting the development of individualized treatment of tumors, and achieve the effects of preventing drug waste, reducing the burden, and reducing the burden on patients.

Active Publication Date: 2018-12-07
CANCER INST & HOSPITAL CHINESE ACADEMY OF MEDICAL SCI
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Therefore, tumor monitoring methods have seriously restricted the development of individualized tumor treatment, and have become a bottleneck to be solved urgently.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Gene mutation site for predicting anti-HER2 therapeutic drug reactivity of patients with breast cancer and application thereof
  • Gene mutation site for predicting anti-HER2 therapeutic drug reactivity of patients with breast cancer and application thereof
  • Gene mutation site for predicting anti-HER2 therapeutic drug reactivity of patients with breast cancer and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0052] Example 1 Screening for gene mutation sites associated with drug resistance in breast cancer patients

[0053] 1. Patient and sample collection

[0054] A total of 120 female ABC patients who were being treated in a tumor hospital were collected. These patients were diagnosed as breast cancer by pathological examination; among them, 119 patients had non-invasive ductal carcinoma, and 1 patient had bone marrow carcinoma.

[0055] The level of HER2 positivity was defined by immunohistochemistry 3+, or immunohistochemistry 2+ / fluorescence in situ hybridization+ (FISH+). The breast cancer patients in this study were patients over 18 years old who were diagnosed with metastatic breast cancer. The patient's peripheral blood was collected using streck tubes and centrifuged within 72 hours to separate plasma from peripheral blood cells. This study was approved by the ethics committees of the Chinese Academy of Medical Sciences and the National Cancer Center / Tumor Hospital of ...

Embodiment 2

[0074] Example 2 HER2 point mutation c.3020C>T anti-HER2 therapeutic cell test

[0075] 1. Experimental materials

[0076] 1. Strains

[0077] Escherichia coli DH5α, stbl3, is preserved by the State Key Laboratory of Molecular Oncology, Chinese Academy of Medical Sciences (hereinafter referred to as "Key Laboratory").

[0078] 2. Plasmid

[0079] LentiCRISPRV2: Lentiviral expression vector, donated by the laboratory of Dr. Zhang Feng of the Massachusetts Institute of Technology, and its gel recovery product is preserved by the key laboratory.

[0080] LenticrisprV2-HER2: A lentiviral expression vector inserted into the corresponding sgRNA, constructed by this application. (See the experimental method section below for the specific construction method)

[0081] PCMV-GFP: green fluorescent protein lentiviral expression vector, preserved by key laboratories.

[0082] 3. Cell lines

[0083] BT474: Breast cancer cell line, preserved by key laboratories.

[0084] Cell line me...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a gene mutation site for predicting the anti-HER2 therapeutic drug reactivity of patients with breast cancer and application thereof. By a large scale of screening, the inventor discovers for the first time that the 3020 site of the HER2 gene coding sequence is related to the drug reactivity of patients with breast cancer on trastuzumab, lapatinib or pyrotinib. Based on theresearch result, a product for predicting the drug reactivity of a patient with breast cancer on trastuzumab, lapatinib or pyrotinib is developed. The product can be widely applied to clinical application by detecting the function of the 3020 site genome of the HER2 gene coding sequence.

Description

technical field [0001] The invention belongs to the field of medicine, and relates to gene mutation sites for predicting the responsiveness of breast cancer patients to anti-HER2 therapeutic drugs, in particular to HER2 for predicting the drug responsiveness of breast cancer patients to trastuzumab, lapatinib or pyrotinib Gene mutation sites and their applications. Background technique [0002] Human epidermal growth factor receptor 2 (HER2) is overexpressed in 20-30% of breast cancer patients, and HER2 overexpression is associated with poor prognosis and high-grade malignancy. HER2 protein overexpression or HER2 gene amplification is also an important predictive biomarker for identifying breast cancer patients who would benefit from HER2-targeted therapy. Several preclinical and clinical studies have shown that the mechanism of HER2 activation involves not only HER2 protein overexpression and gene amplification, but also somatic mutations capable of activating HER2. The e...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/6886C12N15/12
CPCC07K14/71C12Q1/6886C12Q2600/106C12Q2600/156
Inventor 马飞徐兵河易宗毕管秀雯刘斌亮李春晓
Owner CANCER INST & HOSPITAL CHINESE ACADEMY OF MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com